New Immune Target in Dry Eye

Investigators say rexinoid therapy may represent a new class of dry eye treatment focused on regenerative immune signaling

June 30, 2026
3 min

The Ophthalmologist

Objective:

To investigate the effects of the synthetic rexinoid compound NEt-3IB on ocular surface inflammation and goblet cell preservation in a mouse model of dry eye disease.

Approach:

Study Design: Preclinical study using a mouse model of desiccation-induced dry eye disease.
Treatment: Mice were treated with topical NEt-3IB three times daily for five days.
Analysis: Single-cell RNA sequencing was used to assess changes in conjunctival macrophages.

Key Findings:

NEt-3IB reduced ocular surface inflammation and preserved goblet cells.
The treatment shifted conjunctival macrophages from an inflammatory to a homeostatic state.
Corneal permeability assays showed less epithelial barrier disruption in treated mice.
NEt-3IB increased expression of reparative factors Igf1 and Il10, unlike dexamethasone.
NEt-3IB caused only transient increases in intraocular pressure, unlike prolonged dexamethasone treatment.